NASDAQ:MRVI

Maravai LifeSciences (MRVI) Stock Price, News & Analysis

Maravai LifeSciences logo
$7.40 -0.14 (-1.86%)
Closing price 04:00 PM Eastern
Extended Trading
$7.42 +0.01 (+0.20%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Maravai LifeSciences Stock (NASDAQ:MRVI)

Advanced

Key Stats

Today's Range
$7.09
▼
$7.60
50-Day Range
$6.53
▼
$8.52
52-Week Range
$2.80
▼
$9.42
Volume
1.51 million shs
Average Volume
2.22 million shs
Market Capitalization
$1.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.10
Consensus Rating
Moderate Buy

Company Overview

Maravai LifeSciences provides products and services used by biotechnology and pharmaceutical companies in the development and production of therapeutics, vaccines, and other biologic products. Its offerings include specialized nucleic acid materials and analytical testing services that support research, manufacturing, and quality control.

Through TriLink BioTechnologies, the company supplies modified nucleotides, custom RNA and DNA, and related materials used in applications such as messenger RNA research and production. Its Cygnus Technologies business provides testing and analytical services focused on detecting process-related impurities in biologics.

Maravai serves life sciences customers in the United States and internationally. Its businesses support customers across the development and manufacturing process, including with tools for nucleic acid-based medicines and biologics safety testing.

AI Generated. May Contain Errors.

Maravai LifeSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

MRVI MarketRank™: 
1.820832228995 of 5 stars

Maravai LifeSciences scored higher than 36% of companies evaluated by MarketBeat, and ranked 731st out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Maravai LifeSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Maravai LifeSciences is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Maravai LifeSciences has only been the subject of 4 research reports in the past 90 days.

  • Read more about Maravai LifeSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.16) to ($0.14) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Maravai LifeSciences is -17.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Maravai LifeSciences is -17.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Maravai LifeSciences has a P/B Ratio of 5.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.55% of the float of Maravai LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Maravai LifeSciences has a short interest ratio ("days to cover") of 6.81.
  • Change versus previous month

    Short interest in Maravai LifeSciences has recently increased by 5.28%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Maravai LifeSciences does not currently pay a dividend.

  • Dividend Growth

    Maravai LifeSciences does not have a long track record of dividend growth.

  • News Sentiment

    Maravai LifeSciences has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Maravai LifeSciences this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    3 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    2.49% of the stock of Maravai LifeSciences is held by insiders.

  • Percentage Held by Institutions

    50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Maravai LifeSciences' insider trading history.
Receive MRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MRVI Stock News Headlines

Maravai LifeSciences (NASDAQ:MRVI) Raised to Overweight at KeyCorp
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
Maravai LifeSciences (NASDAQ:MRVI) Upgraded at Wall Street Zen
Analyzing Maravai LifeSciences (NASDAQ:MRVI) and Icon (NASDAQ:ICLR)
Maravai LifeSciences (MRVI) Q3 2026 Earnings Call Transcript
See More Headlines

MRVI Stock Analysis - Frequently Asked Questions

Maravai LifeSciences' stock was trading at $3.25 on January 1st, 2026. Since then, MRVI shares have increased by 127.7% and is now trading at $7.40.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) issued its quarterly earnings results on Wednesday, November, 4th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.03. The company had revenue of $45.85 million for the quarter, compared to analyst estimates of $43.56 million. Maravai LifeSciences had a negative trailing twelve-month return on equity of 12.44% and a negative net margin of 30.83%.
Read the conference call transcript
.

Maravai LifeSciences (MRVI) raised $1.5 billion in an initial public offering on Thursday, November 19th 2020. The company issued 60,000,000 shares at $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Top institutional investors of Maravai LifeSciences include First Eagle Investment Management LLC (1.26%), State Street Corp (1.18%), Marshall Wace LLP (0.78%) and Royce & Associates LP (0.66%). Insiders that own company stock include Gtcr Investment Xi Llc, Bernd Brust, Kurt Oreshack, Carl Hull and Gregory T Lucier.
View institutional ownership trends
.

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Maravai LifeSciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CrowdStrike (CRWD), Palantir Technologies (PLTR), Alibaba Group (BABA) and Pfizer (PFE).

Company Calendar

Last Earnings
11/04/2026
Today
11/16/2026
Jefferies Global Healthcare Conference
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:MRVI
CIK
1823239
Fax
N/A
Employees
410
Year Founded
2014

Price Target and Rating

High Price Target
$11.00
Low Price Target
$6.00
Potential Upside/Downside
+9.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$130.77 million
Net Margins
-30.83%
Pretax Margin
-54.19%
Return on Equity
-12.44%
Return on Assets
-6.66%

Debt

Debt-to-Equity Ratio
0.51
Current Ratio
4.66
Quick Ratio
2.98

Sales & Book Value

Annual Sales
$185.74 million
Price / Sales
10.36
Cash Flow
$0.40 per share
Price / Cash Flow
18.35
Book Value
$1.31 per share
Price / Book
5.65

Miscellaneous

Outstanding Shares
259,940,000
Free Float
253,467,000
Market Cap
$1.92 billion
Optionable
Optionable
Beta
0.61

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:MRVI) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners